Mustang Bio, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Manuel Litchman M.D.
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 377 Plantation Street Worcester MA United States of America 01605
- IPO Date
- Aug 22, 2017
- CIK
- 0001680048
- Website
- mustangbio.com
- Similar Companies
- Business
- Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Company News
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mustang Bio Announces Closing of $8 Million Public Offering
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio Announces Reverse Stock Split
Mustang Bio Receives Positive Listing Determination from Nasdaq
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Why are Mustang Bio shares (MBIO) up almost 500%?
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Why Is Mustang Bio (MBIO) Stock Up 58% Today?
HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)